Baxter International Inc. reported fourth-quarter sales of $3.9 billion, an 11% increase on a reported basis. U.S. GAAP diluted earnings per share (EPS) was $0.36, and adjusted diluted EPS was $0.88. The company is implementing a new operating model and planning a spinoff of Renal Care and Acute Therapies businesses.
Fourth-quarter sales increased 11% on a reported basis, 17% on a constant currency basis, and 2% on an operational basis.
U.S. sales increased 25% on a reported basis but declined 1% on an operational basis.
Net income attributable to Baxter was $181 million, or $0.36 per diluted share, on a U.S. GAAP basis.
Adjusted net income attributable to Baxter totaled $444 million, or $0.88 per diluted share.
Baxter expects sales growth of 1% to 2% on a reported basis and flat to 1% on a constant currency basis for full-year 2023. The company expects U.S. GAAP earnings of $1.43 to $1.63 per diluted share and adjusted earnings of $2.75 to $2.95 per diluted share.
Visualization of income flow from segment revenue to net income